Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.18 USD

42.18
890,330

+1.07 (2.60%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $42.20 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.

Earnings Estimates Moving Higher for QIAGEN (QGEN): Time to Buy?

by Zacks Equity Research

QIAGEN (QGEN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt

by Zacks Equity Research

Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.

Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod

by Zacks Equity Research

Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.

QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff

by Zacks Equity Research

QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

How QIAGEN (QGEN) Stock Stands Out in a Strong Industry?

by Zacks Equity Research

QIAGEN (QGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

QGEN vs. RGEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

QGEN vs. RGEN: Which Stock Is the Better Value Option?

Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics

by Zacks Equity Research

Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics

5 Stocks Trading Near 52-Week High That Can Scale Higher

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Urmimala Biswas headshot

5 Coronavirus-Proof PEG Picks Suitable for GARP Investors

by Urmimala Biswas

PEG-based investing can be more rewarding with the addition of a few other relevant parameters amid coronavirus-led market rattle.

Can Qiagen (QGEN) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Qiagen (QGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up

by Zacks Equity Research

QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.

QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales

by Zacks Equity Research

QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.

QIAGEN Launches Assay for Cancer Patients Following FDA's Nod

by Zacks Equity Research

QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.

QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1

by Zacks Equity Research

Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.

ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ALXN vs. QGEN: Which Stock Is the Better Value Option?

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

by Sanghamitra Saha

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Sweta Jaiswal, FRM headshot

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

by Sweta Jaiswal, FRM

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.

Trina Mukherjee headshot

Can Economic Stimulus Save MedTech From Coronavirus Doldrums?

by Trina Mukherjee

Following the announcement of the agreement to pass the historic stimulus bill, we look into four MedTech stocks that stand to gain from the same.

Varian Unveils Proton Treatment Planning Eclipse v16 System

by Zacks Equity Research

The launch of this system is a step forward in Varian's (VAR) commitment toward strengthening its Proton Solutions segment.

Abbott (ABT) Rides on Point-of-Care Coronavirus Test Launch

by Zacks Equity Research

Abbott (ABT) launches a portable molecular point-of-care test to speed up coronavirus detection, especially in areas with severe outbreaks.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) on its strong segmental results in the fourth quarter of 2019.

Medtronic's Evolut TAVR System Shows Positive Study Results

by Zacks Equity Research

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.